Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First nine months ended September 30, 2025
Business Overview: Novo Nordisk is a global healthcare company focused on diabetes, obesity, and rare diseases. The period was characterized by robust sales growth driven by GLP-1 treatments, offset by significant one-off restructuring costs related to a company-wide transformation aimed at streamlining operations and reallocating resources to growth areas.
Key Financial Metrics (9M 2025)
| Metric | 9M 2025 (DKK million) | 9M 2024 (DKK million) | Growth (Reported) | Growth (CER*) |
|---|---|---|---|---|
| Net Sales | 229,920 | 204,720 | 12% | 15% |
| Operating Profit | 95,922 | 91,602 | 5% | 10% |
| Net Profit | 75,543 | 72,758 | 4% | N/A |
| Adjusted Net Profit | 87,748 | 80,042 | 10% | N/A |
| Free Cash Flow | 63,887 | 71,760 | (11%) | N/A |
| Capital Expenditure (PP&E) | 41,711 | 31,063 | 34% | N/A |
| Operating Margin | 41.7% | 44.7% | -3.0 pp | N/A |
| Net Profit Margin | 32.9% | 35.5% | -2.6 pp | N/A |
*CER: Constant Exchange Rates (average 2024 rates).
Material Changes vs. Prior Period
- Restructuring Impact: Operating profit growth was significantly impacted by approximately DKK 9 billion in one-off restructuring costs related to a company-wide transformation. Excluding these costs, operating profit would have increased by 15% (reported) and 21% (CER).
- Sales Growth Drivers:
- Obesity Care: Sales surged 37% (reported) / 41% (CER) to DKK 59.9 billion, driven primarily by Wegovy (up 49% reported / 54% CER).
- Diabetes Care: Sales grew 5% (reported) / 8% (CER). GLP-1 diabetes sales grew 7% (reported) / 10% (CER), while insulin sales remained flat at 1% (reported) / 3% (CER).
- Rare Disease: Sales increased 10% (reported) / 13% (CER).
- Geographic Performance: US Operations sales grew 12% (reported) / 15% (CER), positively impacted by gross-to-net adjustments. International Operations sales grew 13% (reported) / 16% (CER).
- Cost Structure: Gross margin declined from 84.6% to 81.0% due to restructuring costs, impairments, and amortization related to the acquisition of former Catalent manufacturing sites. R&D costs increased 9% (reported) / 10% (CER), partly due to restructuring charges and increased late-stage clinical trial activity.
Guidance, Outlook, and Management Commentary
Full-Year 2025 Outlook (Updated)
- Sales Growth: Expected to be 8-11% at CER (previously 8-14%). Reported growth expected to be ~4 percentage points lower than CER due to exchange rates.
- Operating Profit Growth: Expected to be 4-7% at CER (previously 4-10%). Reported growth expected to be ~6 percentage points lower than CER.
- Free Cash Flow: Expected to be between DKK 20-30 billion (excluding potential business development impacts).
- Capital Expenditure: Revised down to around DKK 60 billion (previously DKK 65 billion).
Management Commentary & Risks
- Guidance Narrowing: The narrowing of guidance ranges reflects lowered growth expectations for GLP-1 treatments in diabetes and obesity due to intensifying competition and pricing pressure, particularly in the US.
- Transformation: The company is reducing its global workforce by approximately 9,000 positions (including 5,000 in Denmark) to improve decision-making speed and reallocate resources. Savings are expected to be reinvested in growth opportunities.
- Acquisitions: Novo Nordisk agreed to acquire Akero Therapeutics (USD 4.7 billion) for its MASH pipeline and Omeros' zaltenibart for rare blood disorders. These are expected to impact 2026 operating profit growth negatively by around 3 percentage points.
- Regulatory & Legal:
- US FDA approved Wegovy for MASH treatment.
- A class-action lawsuit was filed in August 2025 regarding financial forecasts and compounded GLP-1 markets; management does not expect a material financial impact.
- Novo Nordisk accepted the US Inflation Reduction Act's Maximum Fair Price for Ozempic, Rybelsus, and Wegovy in Medicare Part D, effective January 2027.
Key Facts for Investor Verification
- Restructuring Costs: Verify the timing and magnitude of the DKK 9 billion one-off restructuring charge and its specific impact on Q3 vs. full-year profitability.
- US Gross-to-Net Adjustments: Confirm the sustainability of the DKK 5 billion positive impact from US gross-to-net sales adjustments included in the 9M results.
- Obesity Market Dynamics: Assess the impact of "mass compounding" of GLP-1s on Wegovy sales volume and pricing in the US, despite the FDA grace period expiry.
- Supply Chain Capacity: Monitor the progress of capital expenditures (DKK 41.7 billion YTD) to ensure they meet the demand for GLP-1 products and mitigate supply constraints noted in International Operations.
- Acquisition Integration: Track the closing timeline and financial integration of the Akero Therapeutics acquisition and its impact on the 2026 R&D budget.